Amarin Co. plc (NASDAQ:AMRN) has received a consensus rating of “Hold” from the six research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.00.
Several research firms recently issued reports on AMRN. Cantor Fitzgerald set a $10.00 price objective on Amarin and gave the company a “buy” rating in a report on Monday. ValuEngine downgraded Amarin from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Zacks Investment Research downgraded Amarin from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. Finally, BidaskClub downgraded Amarin from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st.
Amarin (NASDAQ AMRN) traded up $0.07 during mid-day trading on Wednesday, hitting $3.67. The company had a trading volume of 971,478 shares, compared to its average volume of 2,160,000. The company has a debt-to-equity ratio of -1.12, a current ratio of 1.41 and a quick ratio of 1.13. The stock has a market cap of $1,060.00, a P/E ratio of -14.68 and a beta of 0.57. Amarin has a 52-week low of $2.85 and a 52-week high of $4.60.
In other Amarin news, General Counsel Joseph T. Kennedy sold 51,106 shares of the company’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $4.10, for a total transaction of $209,534.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Joseph T. Kennedy sold 44,857 shares of the company’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $3.73, for a total value of $167,316.61. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 426,720 shares of company stock worth $1,814,296. 3.72% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. OppenheimerFunds Inc. increased its holdings in Amarin by 20.9% during the 4th quarter. OppenheimerFunds Inc. now owns 7,897,310 shares of the biopharmaceutical company’s stock worth $31,668,000 after purchasing an additional 1,365,720 shares during the period. Clearbridge LLC boosted its position in shares of Amarin by 9.8% during the 4th quarter. Clearbridge LLC now owns 4,867,366 shares of the biopharmaceutical company’s stock worth $19,518,000 after acquiring an additional 435,340 shares in the last quarter. Alkeon Capital Management LLC acquired a new position in shares of Amarin during the 3rd quarter worth about $7,875,000. Two Sigma Investments LP boosted its position in shares of Amarin by 41.1% during the 4th quarter. Two Sigma Investments LP now owns 1,547,977 shares of the biopharmaceutical company’s stock worth $6,207,000 after acquiring an additional 450,755 shares in the last quarter. Finally, Highland Capital Management LP boosted its position in shares of Amarin by 152.5% during the 4th quarter. Highland Capital Management LP now owns 1,197,000 shares of the biopharmaceutical company’s stock worth $4,800,000 after acquiring an additional 723,000 shares in the last quarter. Institutional investors own 38.20% of the company’s stock.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.